| Primary information |
|---|
| sequence ID | Seq_7978 |
| Peptide sequence | SYKMADEAGSEADHEGTHSTKRGHA |
| CancerPDF_ID | CancerPDF_ID559, CancerPDF_ID1260, CancerPDF_ID1320, CancerPDF_ID2403, CancerPDF_ID8526, CancerPDF_ID9705, CancerPDF_ID9706, |
| PMID | 19795908,21136997,21136997,21136997,23667664,21533267,21533267 |
| Protein Name | Fibrinogen alpha chain,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha,Fibrinogen alpha chain,Fibrinogen alpha chain |
| UniprotKB Entry Name | FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN,FIBA_HUMAN |
| Fluid | Plasma,Serum,Serum,Plasma,Serum,Serum,Serum |
| M/Z | 891.392,2671.1681,2687.16302,2671.1681,2671.17,668.78,672.78 |
| Charge | 3,1,1,1,1,4,4 |
| Mass (in Da) | NA,NA,NA,NA,2673.8,NA,NA |
| fdr | NA,NA,NA,NA,NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,LC-MS,LC-MS,MALDI-TOF,LC-MS,LC-MS |
| Peptide Identification technique | MALDI-TOF/TOF,LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,LC/MS/MS |
| Quantification Technique | LC-MRM (multiple reaction monitoring),LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,NA,Multiple Reaction Monitoring,Multiple Reaction Monitoring |
| Labelled/Label Free | Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free |
| FDR | less than 7%,NA,NA,NA,NA,1.49,1.49 |
| CancerPDF_ID | CancerPDF_ID559, CancerPDF_ID1260, CancerPDF_ID1320, CancerPDF_ID2403, CancerPDF_ID8526, CancerPDF_ID9705, CancerPDF_ID9706, |
| p-Value | NA,NA,NA,NA,NA,NA,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT,MASCOT,MASCOT |
| Length | 25,25,25,25,25,25,25 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Colorectal cancer,Colorectal cancer,Normal,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,SwissProt Database,SwissProt Database,SwissProt Database,NA,Swissprot Database (57.4),Swissprot Database (57.4) |
| Modification | NA,NA,Oxidation of Met,NA,NA,NA,Oxidation |
| Number of Patients | "42 normal, 28patients",30 patients and 30 healthy controls,30 patients and 30 healthy controls,27 healthy individuals,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,NA,NA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | NA,Leave One out Cross validation,Leave One out Cross validation,Leave One out Cross validation,NA,MRM-based validation of 19 candidates,MRM-based validation of 19 candidates |
| Sensitivity | NA,NA,NA,NA,NA,NA,NA |
| Specificity | NA,NA,NA,NA,NA,NA,NA |
| Accuracy | NA,NA,NA,NA,NA,NA,NA |
| Peptide Atlas | NA |
| IEDB | |